I-Mab’s Givastomig Study Accepted for ESMO GI 2025 Presentation

The latest announcement is out from I-MAB ( (IMAB) ).

On April 30, 2025, I-Mab announced that an abstract for a study involving their bispecific antibody, givastomig, was accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona. The study, which combines givastomig with nivolumab and chemotherapy, has shown promising results in Phase 1 trials for metastatic gastric cancers, indicating potential advancements in cancer treatment. This acceptance highlights I-Mab’s ongoing efforts to solidify its position in the biotech industry, particularly in the field of precision immuno-oncology.

Spark’s Take on IMAB Stock

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

More about I-MAB

I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment. The company operates from Rockville, Maryland, and Short Hills, New Jersey, and collaborates globally, sharing rights with partners like ABL Bio, excluding Greater China and South Korea.

YTD Price Performance: -10.99%

Average Trading Volume: 237,610

Technical Sentiment Signal: Buy

Current Market Cap: $63.72M

For detailed information about IMAB stock, go to TipRanks’ Stock Analysis page.